Your browser doesn't support javascript.
loading
Clinical application of Xingnaojing Injection in treatment of 11 674 cases of cerebral infarction: a real world study / 中国中药杂志
China Journal of Chinese Materia Medica ; (24): 2329-2334, 2020.
Artículo en Chino | WPRIM | ID: wpr-827944
ABSTRACT
To analyzed the actual clinical application of Xingnaojing Injection in treating cerebral infarction in the real world, selected HIS(hospital information system) database of inpatients in 39 hospitals across the country, and conducted descriptive analysis and association rule analysis on the information of 11 674 patients with cerebral infarction using Xingnaojing Injection. The results showed that the average age of the patients was 69.69 years. TCM syndrome of phlegm stasis and collaterals stagnation was the most(37.56%), followed by wind-phlegm obstruction of collaterals(19.01%). Virtual syndrome accounted for 21.06%. Intravenous drip was the most important route of administration(96.50%). Iv infusion single dose of 10-20 mL(52.44%), other off-label doses accounted for a larger proportion(47.56%). Continuous use of the drug within 3 days(55.45%), 15-28 days accounted for 6.96%, >28 days accounted for 0.89%. The top 10 Western drugs used in combination mainly include antihypertensive drugs, acid-suppressing drugs to protect stomach, drugs to improve brain circulation, drugs to protect brain nerves and drugs to fight infection. The top 10 of Chinese patent medicines are mainly activating blood circulation and removing stasis, clearing heat and clearing the surface, etc. According to the analysis of association rules, three types of clinical drug use modes for the combination of Chinese and Western medicine were obtained, mainly including the first type Xingnaojing Injection+nifedipine(nifedipine, nifedipyridine, Lixinping)+levoflo-xacin+Huayu Tongmai agent. The second category Xingnaojing Injection+omeprazole+edaravone+Huayu Tongmai agent; The third category Xingnaojing Injection+ganglioside and ganglioside derivatives+edaravone+Huayu Tongmai agent. The results show that Xingnaojing Injection is not a standard drug in the treatment of cerebral infarction. At the same time, the combined use of drugs is mainly recommended by the guidelines and conventional treatment drugs, reflecting the clinical application of integrated traditional Chinese and Western medicine.
Asunto(s)

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Medicamentos Herbarios Chinos / Infarto Cerebral / Usos Terapéuticos / Quimioterapia / Inyecciones / Medicina Tradicional China Tipo de estudio: Estudio diagnóstico / Guía de Práctica Clínica Límite: Anciano / Humanos Idioma: Chino Revista: China Journal of Chinese Materia Medica Año: 2020 Tipo del documento: Artículo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponible Índice: WPRIM (Pacífico Occidental) Asunto principal: Medicamentos Herbarios Chinos / Infarto Cerebral / Usos Terapéuticos / Quimioterapia / Inyecciones / Medicina Tradicional China Tipo de estudio: Estudio diagnóstico / Guía de Práctica Clínica Límite: Anciano / Humanos Idioma: Chino Revista: China Journal of Chinese Materia Medica Año: 2020 Tipo del documento: Artículo